Clinical trials

Easy-peasy Series-B(sy)

Nuritas launches PeptiYouth™ an AI-discovered peptide, clinically proven, anti-aging molecule. Nuritas, a leader in Artificial Intelligence-based peptide discovery, has launched PeptiYouth™, a peptide discovered within peas and which, following clinical trials, has been shown...

Machine learning to de-risk clinical trials

Insilico and Oxford University used machine learning to predict major clinical forms of drug cardiotoxicity. Insilico Medicine announced this week that they, in partnership with...

Move over AI? Here comes biological intelligence

Braincures raising funds to take-on AI drug discovery for Alzheimer’s and other neurological diseases with data analysis and systems biology. The treatment of neurological diseases...

New Japanese stem cell clinical trial for aging frailty

Longeveron announces Phase 2 clinical trial to evaluate the safety and efficacy of Mesenchymal Stem Cells (LMSCs) for the treatment of aging frailty in...

Alkahest announces phase 2 study treatment of cognitive impairment

Extra-corporeal medical device could improve neuro outlook for end-stage renal disease patients. Alkahest has announced its first foray into dialysis-associated dementia with a new randomised,...

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...

New young blood plasma research creates a stir

Indian start-up Nugenics Research to commercialise “Elixir” after showing 54% age reversal in animal study. The topic of using blood plasma to address human Longevity...

Applying theoretical physics to Longevity drug discovery

Peter Fedichev's Gero raising $10 million for anti-aging drug discovery and clinical trials. The use of AI in Longevity drug discovery is nothing new, Insilico...

Regenerative medicine start-up raises $28.5 million

A Baltimore based biotech start-up, LifeSprout, has closed a $28.5million round of series A financing as it prepares for the launch of clinical trials...

Longevity and the art of motorcycle maintenance

OpenCures' Kevin Perrott talks about empowering the consumer with their own health data. One of the Longevity sector’s leading voices came to the field relatively...

Longevity2020: Day 2 recap

Yesterday at Longevity2020 was all about rejuvenation therapies, bringing together some of the world’s leading luminaries in the fight against aging. Things kicked off with...

Longevity2020: Day 1 recap

The first day of Longevity2020 kicked off yesterday as we welcomed some of the big names in Longevity to the virtual stage. Curated by AgeCurve’s...

BioViva to spin out its R&D and bioinformatics

CEO in the front-line: Liz Parrish talks gene therapy, patient data and funding. From academics and entrepreneurs to engineers and technologists, the battle against aging...

Oisín on aging as a disease and raising $5m seed

Co-founder Gary Hudson talks cell senescence, trials, spin-outs and the dilemma of treating age as a disease. Every entrepreneur in Longevity has a different story...

Juvenescence CEO on near-term Longevity breakthroughs

We talk pipeline, trials, raising capital and public company challenges with Juvenescence's Dr Greg Bailey. Longevity.Technology: Longevity is growing as a distinct investment category and Thursday’s...

The quest to define biological age

Prof Steve Horvath, the founder of epigenetic age measurement, talks methylation clocks and the need for standardisation. A key speaker on the subject will be...

Building faster and better age-related clinical trials

Prof Ilaria Bellantuono seeks to build faster, better clinical trials for age-related disease with a focus on frailty. Multimorbidity – an individual suffering two or...

COVID-19: Leading clinician calls for focus on the biology of aging

Dr Nir Barzilai predicts that rapamycin could decrease severity of coronavirus in the elderly by 50%. Longevity.Technology: When it comes to the world of Longevity...

Global investment consortium slated to back Telocyte into Phase 1

Telomerase therapy ready for human Alzheimer’s trials. “There have been more than 400 registered trials for Alzheimer's and, by global consensus, every single one has...

Chemical screening to find hidden Longevity gems?

Start-up NemaLife evolves from platform technology to services provider to identify chemicals that have both positive and negative effects on Longevity. The use of the...

Latest articles

Selfie biomarkers: AI and insurtech implications for Longevity

AI firm Lapetus targets the face as a biomarker of aging: one simple picture can open-up a host of opportunities and implications. Wow. Named after...

Low levels of stress hormone contributes to aging

When it comes to the stress hormone cortisol, balance is everything, according to a new study in Germany.  There have been plenty of studies that...

Rejuvenation Roadmap charts life extension progress

We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress. Lifespan.io is a US-based non-profit organisation that seeks to...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...